Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paroxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | GRK2 | P25098 | 4/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paroxetine SCHEMBL9398356 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL9398351 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL2847926 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL6100418 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL5312626 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL33348 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL3854638 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL145268 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL8184989 | 0.99 | CYP3A4 (0.98) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL145267 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-31 | — | — | US | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250186340-A1 | EDIBLE ORAL FILMS, COMPOSITIONS, METHOD OF MANUFACTURE AND PACKAGING SYSTEMS | HANHARAN MADHU (US) | 2025-06-12 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4058029-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022178279-A1 | METHOD AND SYSTEM FOR MANUFACTURING ORAL SOLUBLE FILMS, COMPOSITIONS OF ORAL SOLUBLE FILMS, ORAL SOLUBLE FILMS MADE BY THEREBY, AND METHODS OF USE THEREOF | NOVA THIN FILM PHARMACEUTICALS LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| EP-2696850-B1 | DUAL LANE COATING | AQUESTIVE THERAPEUTICS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220096374-A1 | METHOD AND COMPOSITION FOR MAKING AN ORAL SOLUBLE FILM, CONTAINING AT LEAST ONE ACTIVE AGENT | NOVA THIN FILM PHARMACEUTICALS LLC | 2022-03-31 | — | — | US | disclosed |
| US-20220088201-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220054426-A1 | DUAL LANE COATING | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | CYP2C19, PAICS, CYP2B6 | SLC6A4 1504/4885CYP3A4 25/4885MEN1 2692/4885 |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | GPR139, OPRL1, GRIN2C | SLC6A4 148/4885CYP3A4 1767/4885MEN1 4829/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | SLC6A4 120/4885CYP3A4 143/4885MEN1 2827/4885 |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | GPR139, OPRL1, GRIN2C | SLC6A4 152/4885CYP3A4 2449/4885MEN1 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.